Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Correction: Niclosamide and its analogs are potent inhibitors of Wnt/β-catenin, mTOR and STAT3 signaling in ovarian cancer.

Arend RC, Londoño-Joshi AI, Gangrade A, Katre AA, Kurpad C, Li Y, Samant RS, Li PK, Landen CN, Yang ES, Hidalgo B, Alvarez RD, Straughn JM, Forero A, Buchsbaum DJ.

Oncotarget. 2018 Apr 10;9(27):19459. doi: 10.18632/oncotarget.25151. eCollection 2018 Apr 10.

2.

Niclosamide and its analogs are potent inhibitors of Wnt/β-catenin, mTOR and STAT3 signaling in ovarian cancer.

Arend RC, Londoño-Joshi AI, Gangrade A, Katre AA, Kurpad C, Li Y, Samant RS, Li PK, Landen CN, Yang ES, Hidalgo B, Alvarez RD, Straughn JM, Forero A, Buchsbaum DJ.

Oncotarget. 2016 Dec 27;7(52):86803-86815. doi: 10.18632/oncotarget.13466. Erratum in: Oncotarget. 2018 Apr 10;9(27):19459.

3.

S100A4 promotes pancreatic cancer progression through a dual signaling pathway mediated by Src and focal adhesion kinase.

Che P, Yang Y, Han X, Hu M, Sellers JC, Londono-Joshi AI, Cai GQ, Buchsbaum DJ, Christein JD, Tang Q, Chen D, Li Q, Grizzle WE, Lu YY, Ding Q.

Sci Rep. 2015 Feb 13;5:8453. doi: 10.1038/srep08453.

4.

Inhibition of Wnt/β-catenin pathway by niclosamide: a therapeutic target for ovarian cancer.

Arend RC, Londoño-Joshi AI, Samant RS, Li Y, Conner M, Hidalgo B, Alvarez RD, Landen CN, Straughn JM, Buchsbaum DJ.

Gynecol Oncol. 2014 Jul;134(1):112-20. doi: 10.1016/j.ygyno.2014.04.005. Epub 2014 Apr 13.

PMID:
24736023
5.

Effect of niclosamide on basal-like breast cancers.

Londoño-Joshi AI, Arend RC, Aristizabal L, Lu W, Samant RS, Metge BJ, Hidalgo B, Grizzle WE, Conner M, Forero-Torres A, Lobuglio AF, Li Y, Buchsbaum DJ.

Mol Cancer Ther. 2014 Apr;13(4):800-11. doi: 10.1158/1535-7163.MCT-13-0555. Epub 2014 Feb 19.

6.

Monoclonal antibody-based immunotherapy of ovarian cancer: targeting ovarian cancer cells with the B7-H3-specific mAb 376.96.

Fauci JM, Sabbatino F, Wang Y, Londoño-Joshi AI, Straughn JM Jr, Landen CN, Ferrone S, Buchsbaum DJ.

Gynecol Oncol. 2014 Jan;132(1):203-10. doi: 10.1016/j.ygyno.2013.10.038. Epub 2013 Nov 9.

PMID:
24216048
7.

The Wnt/β-catenin pathway in ovarian cancer: a review.

Arend RC, Londoño-Joshi AI, Straughn JM Jr, Buchsbaum DJ.

Gynecol Oncol. 2013 Dec;131(3):772-9. doi: 10.1016/j.ygyno.2013.09.034. Epub 2013 Oct 11. Review.

PMID:
24125749
8.

The C-terminal region Mesd peptide mimics full-length Mesd and acts as an inhibitor of Wnt/β-catenin signaling in cancer cells.

Lin C, Lu W, Zhang W, Londoño-Joshi AI, Buchsbaum DJ, Bu G, Li Y.

PLoS One. 2013;8(2):e58102. doi: 10.1371/journal.pone.0058102. Epub 2013 Feb 28.

9.

ST6Gal-I protein expression is upregulated in human epithelial tumors and correlates with stem cell markers in normal tissues and colon cancer cell lines.

Swindall AF, Londoño-Joshi AI, Schultz MJ, Fineberg N, Buchsbaum DJ, Bellis SL.

Cancer Res. 2013 Apr 1;73(7):2368-78. doi: 10.1158/0008-5472.CAN-12-3424. Epub 2013 Jan 28.

10.

The impact of novel retinoids in combination with platinum chemotherapy on ovarian cancer stem cells.

Whitworth JM, Londoño-Joshi AI, Sellers JC, Oliver PJ, Muccio DD, Atigadda VR, Straughn JM Jr, Buchsbaum DJ.

Gynecol Oncol. 2012 Apr;125(1):226-30. doi: 10.1016/j.ygyno.2011.12.425. Epub 2011 Dec 9.

11.

Basal-like breast cancer stem cells are sensitive to anti-DR5 mediated cytotoxicity.

Londoño-Joshi AI, Oliver PG, Li Y, Lee CH, Forero-Torres A, LoBuglio AF, Buchsbaum DJ.

Breast Cancer Res Treat. 2012 Jun;133(2):437-45. doi: 10.1007/s10549-011-1763-0. Epub 2011 Sep 14.

Supplemental Content

Loading ...
Support Center